Vitamin D deficiency is widespread among women with breast cancer. Guidelines currently recommend daily supplementation with 400 IU vitamin D3; however, attainment of a circulating level of 25-hydroxyvitamin D defined as sufficient (that is, ≥75 nmol/l) might not be possible with this level of supplementation, according to data published in the Journal of Clinical Oncology.